FDA Guidance Could Impose Drug-Like Burden On Cosmetic Trials
This article was originally published in The Rose Sheet
Executive Summary
An FDA guidance document intended to clarify if firms conducting certain drug studies involving human subjects are obligated to file Investigational New Drug Applications instead raises questions for the cosmetics industry.
You may also be interested in...
Cosmetic Clinical Trials Can Explore Drug Effects Without IND – US FDA Proposed Rule
The proposed rule addresses objections raised by industry in response to the agency’s former position set forth in 2013 guidance. The FDA now proposes two investigational new drug exemption pathways which it says will reduce regulatory burdens while ensuring that study subjects are protected.
FDA Should Strike Cosmetics From IND Guidance – Industry Counsel
By misstating elements of the U.S. Food, Drug and Cosmetic Act, FDA’s guidance on Investigational New Drug applications is in violation of the law, the Personal Care Products Council’s legal head says. FDA surprised stakeholders by including IND requirements for cosmetics in a final guidance released in late 2013, subsequently opening the section up for comments, which were due April 7.
In Brief: IND Applications For Cosmetic Trials? Lauder Appointment; P&G At Olympics
Comments may be submitted through April 7 regarding cosmetics-related sections in an FDA guidance that could impose the costs and burden of Investigational New Drug application on beauty companies conducting clinical trials. More news in brief.